Q1 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
ScemblixⓇ maintains strong launch momentum
Sales evolution
USD m
Ex-US
US
52
10
41
31
25
76
15
61
42
37
29
25
Q1
Q2
Q3
Q4
Q1
2022
2023
TKI tyrosine kinase inhibitor.
GROWTH
OSCEMBLIX®
(asciminib) 20 mg. 40 mg tablets
Q1 sales USD 76 million; US NBRx share at 32%¹
Sales driven by patients resistant/intolerant to other TKIs
Global rollout ongoing with approval in 46 countries; access
pathways in 19, negotiations ongoing in 30+
Increasing recognition of efficacy and tolerability benefit:
G-BA granted the highest ever rating for a medicine in CML
ASC4FIRST (1L registrational study) completed enrollment ahead
of plan, readout and filing expected 2024
NBRX-new to brand prescription. G-BA- German national payer (Gemeinsamer Bundesausschuss). 1. IQVIA: US Jan 2023 rolling three months 3L+ new patient start share.
20 Investor Relations | Q1 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation